Vermont Clinical Trials Report — June 2026

For Vermonters considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for those with specific health conditions or individuals interested in contributing as healthy volunteers. Across the Green Mountain State, 11 clinical trials are slated to close within the next 90 days, meaning time is running out to explore these research options. This includes 2 studies that are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Urgent Opportunities: Trials Nearing Conclusion

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various forms of cancer, heart conditions, and respiratory illnesses are among those with limited time remaining for enrollment. If you or someone you know is affected by these conditions, now is the time to investigate potential participation:

• Acute myeloid leukemia (AML)
• AML with mutated NPM1
• Atrial fibrillation
• Bleeding disorders
• General cancer research
• Chronic granulomatous disease (CGD)
• Chronic obstructive pulmonary disease (COPD)
• COPD acute exacerbation
• Concentric hypertrophy

These trials represent diverse areas of medical inquiry, from advanced cancer treatments to managing chronic heart and lung conditions. The urgency stems from the enrollment periods drawing to a close, after which these specific research opportunities will no longer be available for new participants.

A Significant New Research Initiative for Lung Health

This month, Vermont welcomes 1 new clinical trial, a focused addition compared to 0 new trials in May 2026. While the number is modest, this new study is a significant Phase IIb drug trial from a major pharmaceutical company, offering participants access to cutting-edge research for a serious lung condition.

The notable new trial is:

• NCT07652658: "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This study, sponsored by AstraZeneca, is a Phase IIb trial designed to evaluate the efficacy, safety, and tolerability of 3 different doses of AZD8965 treatment. It aims to compare these doses against a placebo in participants diagnosed with Idiopathic Pulmonary Fibrosis (IPF). Importantly, this trial is open to individuals with IPF who are currently on antifibrotic therapy (such as nintedanib, pirfenidone, or nerandomilast), either alone or in combination, as well as those who are not on antifibrotic treatment. The study plans to enroll 359 participants, representing a substantial effort to advance understanding and treatment for this challenging condition.

This new trial is focused on Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease. The intervention type for this study is a drug, reflecting an industry-led effort by AstraZeneca to develop new therapeutic options.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are still valuable opportunities to contribute to medical science in Vermont. While the single new trial this month does not accept healthy volunteers, there are currently 12 trials statewide that are actively recruiting healthy participants. These studies play a crucial role in establishing baseline data and understanding how treatments or interventions affect individuals without underlying health issues. Among the trials closing soon, 2 are still seeking healthy volunteers, emphasizing the need for prompt action if you are interested in these specific opportunities.

Vermont's Research Landscape: Where to Find Trials

Vermont's clinical research landscape remains active, with a total of 202 clinical trials currently recruiting across 12 cities and 54 research sites statewide. This broad distribution helps ensure that residents in various regions of Vermont have access to cutting-edge research.

This month's new trial is located in:

• Burlington

Burlington continues to be a central hub for clinical investigations in Vermont, hosting the latest research initiatives. The presence of research sites across multiple cities means that individuals throughout the state can often find opportunities closer to home, enhancing accessibility to clinical trials.

Who Can Participate? Eligibility and Demographics

Clinical trials in Vermont are designed to be inclusive, with a broad range of eligibility criteria to ensure research benefits diverse age groups and populations. Of the 1 new trial launched this month, it specifically includes older adults as participants. No new trials this month are exclusively for children, females, or males. This focus on older adults for the new IPF trial is particularly relevant given the prevalence of the condition in this demographic.

The new trial is sponsored by AstraZeneca, highlighting the significant role of industry sponsors in driving drug development and clinical research in the state. This industry-led initiative underscores the commitment to finding new treatments for complex diseases.

As we move through June, the focus remains on encouraging participation in the diverse range of studies available across Vermont, particularly those with impending deadlines and the promising new research for Idiopathic Pulmonary Fibrosis. Your involvement can make a tangible difference in advancing medical knowledge and improving future patient care.